findmyKOL

John Messenger, MD

Basic profile

University of Colorado Anschutz Medical Campus

ORCID↗NPI↗
✓ Full record
RegionAurora, CO · WestSpecialtyInterventional CardiologyFocusCardiology
Active KOLfindmyKOL type: RegionalLatest publication2021Online presenceNot yet checkedPayments2021 onwardNIH funding2006–2007

John Messenger is a Cardiology physician affiliated with University of Colorado Anschutz Medical Campus. OpenAlex indexes 395 publications with 21,516 citations (h-index 65). By OpenAlex citation count, this profile ranks in the top 5% of Interventional Cardiology profiles in the findmyKOL directory.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
395publications

Distinct works indexed by OpenAlex, matched via ORCID.

21,516citations

Total citations across indexed works.

65h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
13companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 2006–2007

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

12605 E 16th Ave
Aurora, CO 800452545

Telephone

720-848-0000

Registry record last updated 1 Feb 2011.

View the NPPES registry record

Industry payments

13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    89.5%
    Statin31.6%
    Rosuvastatin Calcium50%Atorvastatin Calcium50%
    Part D≥39 patients
    PCSK9 Inhibitor17.6%
    Repatha Sureclick81%Praluent Pen19%
    Part D<11 patients

    + 9 more classes in this area

  • Blood & clotting

    7.7%
    P2Y12 inhibitor5.5%
    Clopidogrel62%Brilinta38%
    Part D<11 patients
    Factor Xa inhibitor2.2%
    Xarelto100%
    Part D<11 patients
  • Anti-infectives

    2.8%
    Penicillins with extended spectrum2.8%
    Amoxicillin100%
    Part D≥11 patients
Where care is delivered (Part B)90.5% facility · 9.5% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 2006–2007 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”